PMID- 31506889
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 10
IP  - 6
DP  - 2019 Dec
TI  - Canagliflozin Increases Postprandial Total Glucagon-Like Peptide 1 Levels in the 
      Absence of alpha-Glucosidase Inhibitor Therapy in Patients with Type 2 Diabetes: A 
      Single-Arm, Non-randomized, Open-Label Study.
PG  - 2045-2059
LID - 10.1007/s13300-019-00689-w [doi]
AB  - INTRODUCTION: To investigate canagliflozin-induced changes in postprandial total 
      glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide 
      (GIP) levels in patients with type 2 diabetes mellitus (T2DM). METHODS: 
      Forty-five patients with T2DM who had inadequate glycemic control (glycated 
      hemoglobin >/= 6.5%) with diet and exercise alone (n = 15, drug naive) and in 
      combination with either a stable dose of the alpha-glucosidase inhibitor acarbose 
      (n = 15) or metformin (n = 15) received canagliflozin, a sodium-glucose 
      cotransporter 2 inhibitor, at 100 mg once daily for 12 weeks. The primary 
      endpoint was the change from baseline to week 12 in postprandial glucose and 
      plasma levels of total GLP-1 and GIP during a meal tolerance test (MTT). RESULTS: 
      Canagliflozin significantly reduced postprandial blood glucose (mean difference 
      - 40.2 mg/mL at 60 min) and increased postprandial total GLP-1 (mean difference 
      1.8 pg/mL at 60 min) during an MTT. A transient reduction in the postprandial GIP 
      level at only 30 min (mean difference - 80.3 pg/mL) during an MTT was observed. 
      No changes in postprandial GLP-1 or GIP levels were seen after canagliflozin 
      treatment as an add-on to acarbose in patients with T2DM. Acarbose treatment 
      significantly decreased postprandial total GIP levels (P < 0.05) and tended to 
      increase postprandial total GLP-1 levels (P = 0.07) compared to the other two 
      treatments prior to canagliflozin. CONCLUSION: Canagliflozin 100 mg increased 
      postprandial total GLP-1 levels in the absence of acarbose, suggesting that it 
      may upregulate GLP-1 secretion through delayed glucose absorption in the upper 
      intestine, as with the alpha-glucosidase inhibitor. TRIAL REGISTRATION: University 
      Hospital Medical Information Network, UMIN000018345. FUNDING: Mitsubishi Tanabe 
      Pharma Corporation.
FAU - Osonoi, Takeshi
AU  - Osonoi T
AD  - Naka Kinen Clinic, 745-5 Nakadai, Naka, Ibaraki, 311-0113, Japan.
FAU - Tamasawa, Atsuko
AU  - Tamasawa A
AD  - Naka Kinen Clinic, 745-5 Nakadai, Naka, Ibaraki, 311-0113, Japan.
FAU - Osonoi, Yusuke
AU  - Osonoi Y
AD  - Naka Kinen Clinic, 745-5 Nakadai, Naka, Ibaraki, 311-0113, Japan.
FAU - Ofuchi, Kensuke
AU  - Ofuchi K
AD  - Naka Kinen Clinic, 745-5 Nakadai, Naka, Ibaraki, 311-0113, Japan.
FAU - Katoh, Makoto
AU  - Katoh M
AUID- ORCID: 0000-0002-5216-0271
AD  - Naka Kinen Clinic, 745-5 Nakadai, Naka, Ibaraki, 311-0113, Japan. 
      m-katou@kensei-kai.com.
FAU - Saito, Miyoko
AU  - Saito M
AD  - Naka Kinen Clinic, 745-5 Nakadai, Naka, Ibaraki, 311-0113, Japan.
LA  - eng
PT  - Journal Article
DEP - 20190910
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
PMC - PMC6848431
OTO - NOTNLM
OT  - Canagliflozin
OT  - GLP-1
OT  - SGLT1
OT  - SGLT2 inhibitor
OT  - Type 2 diabetes
EDAT- 2019/09/12 06:00
MHDA- 2019/09/12 06:01
PMCR- 2019/09/10
CRDT- 2019/09/12 06:00
PHST- 2019/07/18 00:00 [received]
PHST- 2019/09/12 06:00 [pubmed]
PHST- 2019/09/12 06:01 [medline]
PHST- 2019/09/12 06:00 [entrez]
PHST- 2019/09/10 00:00 [pmc-release]
AID - 10.1007/s13300-019-00689-w [pii]
AID - 689 [pii]
AID - 10.1007/s13300-019-00689-w [doi]
PST - ppublish
SO  - Diabetes Ther. 2019 Dec;10(6):2045-2059. doi: 10.1007/s13300-019-00689-w. Epub 
      2019 Sep 10.